Talzenna

News

J&J claims first approval for PARP combo Akeega

Johnson & Johnson has picked up its first regulatory approval worldwide for Akeega, a fixed-dose combination of a PARP inhibitor and anti-androgen therapy, as a treatm

News

J&J gets restricted label for PARP drug Akeega in EU

Drug is backed for BRCA+ prostate cancer patients only, a narrower group than rival Lynparza.

News

Lynparza under siege in first-line prostate cancer

New data from Pfizer and J&J encroach on AZ and Merck's territory with the PARP inhibitor.

J&J claims first approval for PARP combo Akeega

J&J gets restricted label for PARP drug Akeega in EU

Lynparza under siege in first-line prostate cancer

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

Editor's Picks